This finding was corroborated by Nagasawa et al., who identified GATA3 mutations as potential recurrence indicators and discovered downregulation of the progesterone receptor, offering new insights into DCIS classification and treatment optimization [116]. This evidence concerns the gene GATA3 and ductal breast carcinoma in situ.